Computational biology

Biswas Family Foundation, Milken Institute Announce $15 Million in Funding for Research at the Intersection of AI and Health

Retrieved on: 
Tuesday, March 12, 2024
Technology, General Health, Infectious Diseases, Foundation, Philanthropy, Science, Biotechnology, Health, Health Technology, Other Philanthropy, Other Science, Research, Other Technology, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Gladstone Institutes, Diagnosis, Health informatics, Harvard Medical School, Computational biology, SPARC, Transformative use, Test management, Computer science, Data science, Disease, Assistant, Massachusetts Institute of Technology, Associate, Chatbot, Partnership, Genetics, Patient, Common, Artificial intelligence, AI, Doctor of Philosophy, Interpretation, Investment, Stanford University, Milken Institute, Genetic distance, Medical device

The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .

Key Points: 
  • The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .
  • Five multidisciplinary research teams will receive nearly $14 million total in grant funding for projects aiming to drive translational impact and the advancement of artificial intelligence (AI) models in clinical settings for diagnosis and treatment.
  • Additional support to enhance AI and computational biology research, inclusive of a gift to the Arc Institute , marks a total of $15 million in giving for the Biswas Family Foundation for this interdisciplinary field, and the beginning of more support.
  • To learn more about the Transformative Computational Biology Grant Program and to read the Giving Smarter Guide, visit: https://bit.ly/3Vae8Kq .

Pelvital Announces Advisory Board, Fueling its Mission to Transform the Standard of Care for Urinary Incontinence

Retrieved on: 
Tuesday, April 2, 2024
University, Obstructive sleep apnea, Patient, Pelvic pain, Vocational education, Urodynamic testing, Engineering, Gender, Champaign–Urbana metropolitan area, Pelvic organ prolapse, Carlson School of Management, UnitedHealth Group, Incontinence, Woman, Safety, Strategic communication, Organization, Biomedical engineering, Advisory board, Neurology, Female, Sport, Associate, Research, MD, UIT, Tetraplegia, Urinary incontinence, Biology, Book, FDA, Medtech, Health, Visibility, Growth, Computational biology, Arizent, Mechanical engineering, Physiology, M Health Fairview, Doctor of Philosophy, Integrative Biology, Faculty, Urogynecology, Human, MBA, News, Government, Rehabilitation, Nursing

EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board. This dynamic team of industry leaders and experts will play a pivotal role in supporting the strategic direction and growth of the organization in its ongoing efforts to expand its reach with clinicians, patients, and payors seeking an effective, accessible, conservative treatment option.

Key Points: 
  • EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board.
  • The seven-person advisory board assembles a wealth of experience and expertise with each member having a proven track record of excellence.
  • Dr. Alpert has taught for many years in entrepreneur programs at U.S. and overseas universities, mentoring students and faculty working in the healthcare industry.
  • Their collective knowledge and experience will be instrumental in guiding Pelvital as we embark on an exciting phase of growth and innovation."

Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry

Retrieved on: 
Tuesday, April 2, 2024
Kitchen, Bioreactor, Computational biology, IIA, Growth, Genetic distance, Generator, AI, Protein, TKH, Strauss Group, Pharming (genetics), USD, Food industry

REHOVOT, Israel, April 2, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments and The Kitchen FoodTech Hub (TKH), the foodtech incubator and investment arm of Israeli food giant Strauss Group, have jointly announced the establishment of Finally Foods Ltd.

Key Points: 
  • The company's mission is to modify plants as "bioreactors" to produce these proteins efficiently and environmentally responsibly.
  • Leveraging Evogene's GeneRator AI technology, the company aims for short R&D cycles and rapid time-to-market.
  • By harnessing the power of our GeneRator AI tech-engine, molecular farming has the potential to revolutionize the food industry and promote healthier diets worldwide."
  • "Establishing the company under the framework of The Kitchen and investing the pre-seed round was an easy decision in this case."

Evogene Announces Filing of Annual Report on Form 20-F

Retrieved on: 
Thursday, March 28, 2024
Contact, Annual, Computational biology, Annual report, Security (finance), Cryptocurrency

REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.

Key Points: 
  • REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.
  • The Annual Report on Form 20-F can be accessed on the Company's investor relations website https://evogene.com/investor-relations/ and on the SEC's website at http://www.sec.gov .
  • The Company's security holders may request a hard copy of the Annual Report free of charge by visiting the Contact Us page of the Company's website.

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 22, 2024
Genomics, Computational biology, Growth, Prevalence, Consumables, Intelligence, DSM-IV codes, Workflow, NGS, DNA, Cancer, Medicine, Nucleotide, Agilent Technologies, Investment, QIAGEN, Safety, Sanger sequencing, Disorder, Table, Vaccine

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.

Key Points: 
  • DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.
  • However, the DNA sequencing market faces hurdles, including technical constraints, high costs, and the complexity of data interpretation, which impede broader adoption.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the DNA Sequencing Market.
  • "Dive into the DNA Sequencing Market Landscape: Explore 196 Pages of Insights, 562 Tables, and 24 Figures"

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 22, 2024
Genomics, Computational biology, Growth, Prevalence, Consumables, Intelligence, DSM-IV codes, Workflow, NGS, DNA, Cancer, Medicine, Nucleotide, Agilent Technologies, Investment, QIAGEN, Safety, Sanger sequencing, Disorder, Table, Vaccine

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.

Key Points: 
  • DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.
  • However, the DNA sequencing market faces hurdles, including technical constraints, high costs, and the complexity of data interpretation, which impede broader adoption.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the DNA Sequencing Market.
  • "Dive into the DNA Sequencing Market Landscape: Explore 196 Pages of Insights, 562 Tables, and 24 Figures"

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Retrieved on: 
Wednesday, March 20, 2024
Computational biology, Letter, Tel Aviv Stock Exchange, Calendar

The Nasdaq Stock Market Rules provide the Company with an additional period of 180 calendar days to regain compliance.

Key Points: 
  • The Nasdaq Stock Market Rules provide the Company with an additional period of 180 calendar days to regain compliance.
  • According to the Letter, the Company has until September 16, 2024, to regain compliance with the minimum bid price requirement.
  • It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company.
  • The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN".

Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform

Retrieved on: 
Wednesday, March 13, 2024
Sequence analysis, Automation, Computational biology, Communication, Drug discovery, Research, AI, Intelligence, Statistics, Drug development, Fine chemical

SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development.

Key Points: 
  • SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development.
  • Additionally, advanced capabilities for sequence analysis, primer design, experimental data processing, and drug development are integrated into the platform.
  • By merging bioinformatics, computational science, statistics, automation technology, and drug screening technology, we have created an Intelligent R&D platform tailored for innovative biopharmaceuticals.
  • The launch of our "Sanyou Intelligent Innovative Biologics R&D Service Platform" will greatly enhance delivery efficiency, quality, and speed, improving communication and accelerating innovative biopharmaceutical research and development."

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Gene editing, AACR, Inflammation, Protein engineering, IPSC, Computational biology, Therapy, Abstract, Autoimmunity

PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA.

Key Points: 
  • PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA.
  • The upcoming abstracts highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, protein engineering and computational biology.
  • Additionally, the Company will share new preclinical data on additional Allo-Evasion™ edits that could further support Century’s multi-dosing strategy.
  • Details of the poster presentations are as follows:
    Full abstracts are currently available through the AACR conference website.

BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer

Retrieved on: 
Monday, February 26, 2024
Doctor of Philosophy, Artificial intelligence, Biotechnology, AI, Statistics, Computational biology, Drug development, Drug discovery, Biomarker, Medicine, Disease, Machine learning, Harvard Medical School, HMS Research, Biology, Bullfrog, Medical device

Prior to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific Machine Learning (SciML) Research and Development Initiative at HiberCell.

Key Points: 
  • Prior to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific Machine Learning (SciML) Research and Development Initiative at HiberCell.
  • At BullFrog AI, Dr. Chittenden will lead the scientific strategy to further develop and implement cutting-edge AI-driven platforms for drug discovery and development.
  • Dr. Chittenden commented, "I am thrilled to join BullFrog AI and to contribute to the Company's innovative approach to drug development.
  • Dr. Chittenden's appointment as Chief Scientific Officer of BullFrog AI, effective February 26, 2024, marks a significant milestone for the Company as it continues to pioneer a new era of AI technology-enabled drug development.